Mazdutide is a synthetic peptide agonist engineered to act at two class B G-protein-coupled receptors: the glucagon-like peptide-1 receptor (GLP-1R) and the glucagon receptor (GCGR). AminoOptimization Group supplies it as a lyophilised research powder in a 5 mg presentation, tested to 99% purity by HPLC, with a Certificate of Analysis available for the lot supplied. This material is offered strictly for laboratory research use. It is not a drug, and it is not for human or veterinary use.
What is Mazdutide?
Mazdutide belongs to a structural family of peptides derived from proglucagon-derived peptide sequences, sharing partial sequence homology with both native GLP-1 and native glucagon. Where each of those native peptides is highly selective for its own receptor, the substitutions carried by mazdutide are described in the literature as conferring measurable agonist activity at both GLP-1R and GCGR from a single molecule — the defining feature that places it in the dual-agonist category rather than the single-receptor GLP-1 analogue category.
The molecular formula, C207H317N45O65, and a molecular weight of 4563.14 g/mol are consistent with a peptide backbone carrying a fatty-acid or fatty-diacid substituent, conjugated through a linker to a lysine side chain. This is a structural strategy used broadly across long-acting peptide analogues to promote reversible, non-covalent binding to serum albumin, a mechanism reported to extend circulating half-life relative to an unmodified peptide of comparable sequence. Additional substitutions at cleavage-susceptible positions are described as conferring resistance to dipeptidyl peptidase-4 (DPP-4), the protease responsible for rapid degradation of native incretin peptides in circulation.
Because it engages two distinct receptors rather than one, mazdutide is studied as a tool for isolating the relative contribution of GLP-1R versus GCGR signalling — work that is largely conducted using unmodified oxyntomodulin, a native peptide with weak affinity at both receptors, as a comparator. The relative potency ratio between the two receptors, and how structural modification shifts that ratio, is the specific subject of most published in vitro characterization of this compound.
Specifications
- Compound: Mazdutide
- CAS number: 2259884-03-0
- Molecular formula: C207H317N45O65
- Molecular weight: 4563.14 g/mol
- Purity: 99% by HPLC
- Presentation: Lyophilised powder, sealed vial
- Available sizes: 5 mg
- Physical form: White to off-white powder
- Classification: Research peptide — not for human or veterinary use
Research context
Published research on GLP-1R/GCGR dual agonists is concentrated at the receptor and cell-signalling level. Radioligand binding assays and cAMP-accumulation assays in receptor-transfected cell lines are used to characterize agonist potency and selectivity at each receptor individually. Structural features such as albumin-binding fatty-acid conjugation are examined for their effect on pharmacokinetic parameters — half-life, clearance, and the duration of measurable receptor engagement — in animal model systems. Separate lines of work examine receptor internalization and desensitization kinetics in cell culture following sustained agonist exposure.
None of this literature establishes safety or efficacy for use in humans. It is provided as research context only.
Reconstitution
Lyophilised peptide requires reconstitution with a suitable sterile diluent before use in solution. Bacteriostatic water is the diluent most commonly specified for multi-use laboratory preparations; sterile water is typical for single-use work.
Direct the diluent stream against the inner wall of the vial rather than onto the powder itself, and allow the material to dissolve without agitation. Peptides are susceptible to shear stress — do not shake the vial. Swirl gently if needed, and expect full dissolution within a few minutes at room temperature.
Working concentration is a function of how much diluent is added to a given vial mass. Our peptide reconstitution calculator computes the resulting concentration for any combination of vial size and diluent volume.
Storage and stability
Before reconstitution: store the sealed vial in a freezer at -20 °C, protected from light. Lyophilised peptide is comparatively stable in this state. Brief excursions to ambient temperature during shipping are normal and are not expected to compromise a properly lyophilised product.
After reconstitution: refrigerate at 2–8 °C and protect from light. Reconstituted peptide in solution is materially less stable than the dry powder. Avoid repeated freeze-thaw cycles, which are a well-documented cause of aggregation and loss of measurable potency — aliquot instead if repeated sampling is required.
Inspect solutions before use. Cloudiness, visible particulate, or discolouration indicate the material should not be relied upon for quantitative work.
Certificate of Analysis
Every lot is tested by high-performance liquid chromatography, and the purity figure shown above refers to analytical results for the specific lot supplied — not to a generic specification. A Certificate of Analysis is available on request, and we will provide lot-specific documentation before purchase if your protocol requires it.
Purity by HPLC describes the proportion of the target peptide relative to detectable related substances. It is a statement about the material as manufactured and tested. It is expressly not a representation that the material is suitable for any use in humans or animals.
Handling and safety
Handle in accordance with good laboratory practice. Use appropriate personal protective equipment, work in a suitable containment environment, and dispose of material and consumables according to your institution’s requirements and applicable local regulation. Anyone with access to this material should understand that it is not for human or veterinary use.
Frequently asked questions
Is Mazdutide approved in Canada?
No. Mazdutide has not been evaluated or authorised by Health Canada for any use, and it carries no Drug Identification Number (DIN) or Natural Product Number (NPN). Its safety and efficacy for human use have not been assessed by Health Canada, the FDA, or any comparable regulatory authority. Any regulatory status this compound may hold in another jurisdiction, under any name, does not extend to Canada and has no bearing on how it is supplied here: strictly for laboratory research use.
What distinguishes Mazdutide from a single-receptor GLP-1 analogue?
A single-receptor GLP-1 analogue is selective for GLP-1R alone. Mazdutide is engineered to retain measurable agonist activity at both GLP-1R and the glucagon receptor (GCGR) from a single molecule, which is why it is classified as a dual agonist and studied as a tool for separating the contribution of each receptor pathway.
How much diluent should be used?
That depends on the working concentration your protocol requires. Use the reconstitution calculator to work out the resulting concentration for your vial size.
How long is reconstituted material usable?
Stability in solution is shorter than in lyophilised form and depends on diluent, temperature, and handling. Refrigerate at 2–8 °C, protect from light, avoid freeze-thaw cycling, and validate stability for your own storage conditions if your work depends on it.
Do you provide a Certificate of Analysis?
Yes — lot-specific, available on request, including before purchase.
Research use only
This product is supplied solely for laboratory and scientific research. It is not a drug, food, cosmetic, or medical device, and it must not be administered to humans or animals. Nothing on this page is medical advice or a therapeutic claim. Full terms are set out in our Research Use Only Disclaimer.
Reviews
There are no reviews yet.